The administration of Nicotinamide mononucleotide(NMN) which is a key precursory metabolite of NAD+ has been reported to have remarkable therapeutic effects on age-related diseases. However systemic evaluation pertaining to the subacute toxicity of NMN remains to be determined.
Recently, the Shanghai Institute of Organic Chemistry conducted a study about the subacute toxicity of NMN in mice and beagle dogs, both of which were gavaged with a saturated concentration of NMN solution at the maximum intragastric dose once or twice per day for 7 or 14 days (Figure 1).
In mice, NMN administrated once per day for 7 days is well tolerated with minimal deleterious effects. Upon higher dosage, they observe a slightly increased level of alanine aminotransferase, while other biomarkers remain unchanged (Figure 2).
Consistently, administration of NMN in beagle dogs only results in mild increases in creatinine and uric acid (Figure 3).
Interestingly, in mice that received higher NMN dosage, measurements of blood lipids, including total cholesterol, triglyceride, and low-density lipoprotein cholesterol, were significantly decreased which indicated that the lipid metabolic process being prominently highlighted (Figure 4).
Despite the administration of NMN was conducted in the short-term, it is sufficient to provide a solid foundation for the security of NMN.
EFFEPHARM focuses on producing superior health material and sharing advanced health information.